D-1491-2016 Class II Terminated

Recalled by Zydus Pharmaceuticals USA Inc — Pennington, NJ

FDA drug recall D-1491-2016 was initiated by Zydus Pharmaceuticals USA Inc on May 9, 2016 and is designated Class II. Reason for recall: Failed impurities/degradation specifications: Out of specification results noticed in related substance test during analysis of 24 months long term (25 degree Celsius /65% RH) stability samples of two… The recall status is terminated (terminated May 1, 2018). Affected quantity: 14,808 bottles.

Recall details

Product Type
Drugs
Report Date
Sep 14, 2016
Initiation Date
May 9, 2016
Termination Date
May 1, 2018
Voluntary/Mandated
Voluntary: Firm initiated
Product Quantity
14,808 bottles

Product description

Bromocriptine Mesylate Capsules USP, 5 mg, 30-count bottles, Rx only, Manufactured by: Cadila Healthcare ltd., Ahmedabad, India Distributed by: Zydus Pharmaceuticals USA Inc., Pennington, NJ 08534, NDC 68382-110-06

Reason for recall

Failed impurities/degradation specifications: Out of specification results noticed in related substance test during analysis of 24 months long term (25 degree Celsius /65% RH) stability samples of two batches.

Distribution pattern

US Nationwide

Code information

Lot # MP993, Exp10/16; MR2704, Exp 02/17; MR6851, MR8100; Exp 07/17 and MR1210, Exp 12/17

Source

Dataset
openFDA drug recall enforcement reports
FDA record
This recall in openFDA (JSON)
Enforcement Report
Search FDA's Enforcement Report for D-1491-2016
openFDA file date
Nov 16, 2026
Loaded by RegDataLab
Nov 17, 2026

These dates say when openFDA published the data file and when RegDataLab last loaded it.

Source: openFDA record for D-1491-2016. Report a data issue: hello@regdatalab.com.